OBJECTIVES: Variceal (VUGIB) and nonvariceal (NVUGIB) upper gastrointestinal bleeding are prevalent causes of hospitalization. Cost estimates are needed to determine the impact of their contemporary treatments (endoscopic hemostasis and high-dose proton pump inhibition). We determined the costs of upper gastrointestinal bleeding with or without complications (rebleeding). METHODS: Charges and length of stay (LOS) were obtained from the United States Nation-wide Inpatient Sample. We defined NVUGIB using Diagnosis Related Groups, and VUGIB using International Classification of Diseases, Ninth Revision, Clinical Modification codes. RESULTS: Hospitalization costs with and without complications were $5632 and $3402 for NVUGIB, and $23,207 and $6612 for VUGIB, respectively; similarly, mean LOS were 4.4 and 2.7 days, and 15.2 and 3.8 days. CONCLUSION: We present hospitalization costs and LOS for VUGIB and NVUGIB with and without complications. The reliability of our estimates rests with the size and the national representativeness of the databases used, and should prove helpful for cost analyses for UGIB requiring updated national estimates.
OBJECTIVES: Variceal (VUGIB) and nonvariceal (NVUGIB) upper gastrointestinal bleeding are prevalent causes of hospitalization. Cost estimates are needed to determine the impact of their contemporary treatments (endoscopic hemostasis and high-dose proton pump inhibition). We determined the costs of upper gastrointestinal bleeding with or without complications (rebleeding). METHODS: Charges and length of stay (LOS) were obtained from the United States Nation-wide Inpatient Sample. We defined NVUGIB using Diagnosis Related Groups, and VUGIB using International Classification of Diseases, Ninth Revision, Clinical Modification codes. RESULTS: Hospitalization costs with and without complications were $5632 and $3402 for NVUGIB, and $23,207 and $6612 for VUGIB, respectively; similarly, mean LOS were 4.4 and 2.7 days, and 15.2 and 3.8 days. CONCLUSION: We present hospitalization costs and LOS for VUGIB and NVUGIB with and without complications. The reliability of our estimates rests with the size and the national representativeness of the databases used, and should prove helpful for cost analyses for UGIB requiring updated national estimates.
Authors: Eric S Orman; Maria E Mayorga; Stephanie B Wheeler; Rachel M Townsley; Hector H Toro-Diaz; Paul H Hayashi; A Sidney Barritt Journal: Liver Transpl Date: 2015-08 Impact factor: 5.799
Authors: Ali S Taha; Caroline McCloskey; Theresa Craigen; Wilson J Angerson; Amir A Shah; Christopher G Morran Journal: Frontline Gastroenterol Date: 2011-07-16
Authors: Ray Boyapati; Sim Ye Ong; Bei Ye; Anuk Kruavit; Nora Lee; Rhys Vaughan; Sanjay Nandurkar; Peter Gibson; Mayur Garg Journal: World J Gastroenterol Date: 2014-08-14 Impact factor: 5.742
Authors: Alan N Barkun; Viviane Adam; Joseph J Y Sung; Ernst J Kuipers; Joachim Mössner; Dennis Jensen; Robert Stuart; James Y Lau; Emma Nauclér; Jan Kilhamn; Helena Granstedt; Bengt Liljas; Tore Lind Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Zinan Yi; Maria E Mayorga; Eric S Orman; Stephanie B Wheeler; Paul H Hayashi; A Sidney Barritt Journal: Transplantation Date: 2017-10 Impact factor: 4.939